MD Anderson and Siemens Healthineers have announced the collaborative development of an education program focused on enabling the implementation of consistent, high-quality MRI in radiation oncology.
A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. This is the first demonstration of a survival advantage with a front-line CDK4/6 inhibitor in postmenopausal patients with
HR+/HER 2- advanced breast cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and neoadjuvant pembrolizumab for advanced solid tumors with mismatch repair deficiencies.
A new study in Science finds that pancreatic cells display an adaptive response to repeated inflammation that initially protects against tissue damage but can promote tumor formation in the presence of mutant KRAS.
MD Anderson to honor the life of trailblazing oncologist Emil J Freireich, M.D., in a virtual tribute event on Sept. 23
A new study from researchers at The University of Texas MD Anderson Cancer Center showed that stereotactic ablative radiotherapy (SABR) was as effective as surgery at providing long-term benefits to patients with operable early-stage non-small cell lung cancer (NSCLC) and generated minimal side effects. The study is the first of its kind to compare long-term results of SABR against surgical treatment in patients with operable early-stage NSCLC.
MD Anderson and SNIPR BIOME have announced a strategic collaboration to advance next-generation CRISPR-based microbiome therapies to reduce immune-related side effects in patients treated with immune checkpoint inhibitors.
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals, Inc. today announced a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe® (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch.
Omer Sultan joins MD Anderson as new Chief Financial Officer
A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
MD Anderson hosts the Leading Edge of Cancer Research Symposium on November 4-5, 2021, featuring presentations from distinguished cancer researchers and a virtual poster session, open to all.
MD Anderson and Blueprint Medicines announced a three-year strategic collaboration to accelerate the development of BLU-222, an investigational targeted therapy against CDK2.
A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.
MD Anderson and Hummingbird Bioscience announced a multi-year strategic research collaboration to investigate HMBD-002, Hummingbird’s VISTA antagonist antibody, as a novel immunotherapy for cancer.
Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.
A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was safe and effective in treating patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) and RET-altered thyroid cancer.
MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.
MD Anderson researchers have developed a first-of-its-kind AI tool to identify rare groups of biologically important cells from the noise of large, complex single-cell datasets. The new tool, called SCMER, can help reserachers gain new insights across many applications.
A metabolic inhibitor drug, IACS-6274, developed by MD Anderson’s Therapeutics Discovery division, is well-tolerated and showed early signs of anti-tumor activity in a Phase I trial being presented at the 2021 ASCO Annual Meeting.
A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant.
MD Anderson and the Broad Institute have launched a translational research platform to study rare cancers. The initiative will lead to a first-of-its-kind resource for the scientific community and will help to accelerate new therapies for patients with rare tumor types.
Atlantic Health System Cancer Care, in partnership with OncLive, invites health care professionals and others interested in the surgical management of melanoma to a virtual lecture by internationally known melanoma expert Charles M. Balch, MD, FACS, FASCO. Dr. Balch is this year’s Joseph Calello Melanoma Scholar. The free lecture and Q & A will be held on May 6, 11 a.m. – 12 p.m. ET.
A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma. The study was published today in the Journal of Clinical Oncology.
MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.
Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to describe the p53 tumor suppressor pathway, which is undermined in many cancers.
A new DNA sequencing approach developed by MD Anderson researchers overcomes technical challenges with earlier techniques to give deeper insights into breast cancer evolution.
Contrary to long-held beliefs, new research finds that collagen in the tumor microenvironment may not promote cancer development but plays a protective role in controlling pancreatic cancer growth. The new findings could have important therapeutic implications.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
MD Anderson researchers have developed a new computational tool to accurately differentiate between cancer cells and normal cells when analyzing large single-cell RNA-sequencing data.
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The University of Texas MD Anderson Cancer Center found that men with localized prostate cancer who reported a baseline dietary pattern that more closely follows the key principles of a Mediterranean-style diet fared better over the course of their disease.
A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the enolase enzyme.
The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas
MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News’ Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division.
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .
Atlantic Health System is enrolling women in a landmark study that uses a simple blood test for the CA-125 protein to screen women who are at low risk for ovarian cancer. The purpose of the clinical trial is to help determine whether this test can catch ovarian cancer early in women who would not normally be screened for it. Atlantic Health System hospitals are the only centers in the New York metro region to participate in the study, and have the third highest enrollment numbers in the nation.
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants, their families and their communities safe and as part of MD Anderson’s commitment to prioritizing the health and safety of patients, workforce members and the greater Houston community.
The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched Cancer Focus Fund, LP, an oncology-focused investment fund designed to support the advancement of compelling investigational cancer therapies from late preclinical development through Phase I and Phase Ib/II clinical trials.
MD Anderson and Allogene today announced a strategic five-year collaboration for preclinical and clinical investigation of allogeneic CAR T cell therapies.
Phase I trial finds neoadjuvant combination checkpoint inhibitors (anti-CTLA-4 plus anti-PD-1) was well tolerated and showed early signs of activity in certain patients with bladder cancer. These patients cannot be treated with chemotherapy and have no standard treatment options available.
A study finds that cancer mutations occur in distinct patterns based on the 3D structure of the genome and the underlying cause of the mutation. This helps us to understand cancer better and may lead to new treatment approaches.
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly, natural-language interface to allow biomedical researchers without specialized expertise in bioinformatics or programming languages to conduct intuitive analysis of large datasets.
MD Anderson News Release September 08, 2020 The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational treatments for patients with a variety of cancer types.
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV) has named 15 new members and bestowed its highest honor of Life Member on senior members Regina Rogers of Beaumont and Melvyn N. Klein of Corpus Christi.
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center. Antibodies to the SARS-CoV-2 spike protein receptor binding domain (S-RBD) are speculated to neutralize virus infection, while the SARS-CoV-2 nucleocapsid protein (N-protein) antibody may often only indicate exposure to the virus, not protections against reinfection.
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational Engineering and Sciences and the Texas Advanced Computing Center (TACC) – today announced a new initiative to build a strong collaboration in Oncological Data and Computational Science.